MPP framework for prioritising target medicines for in-licensing under its newly expanded mandate
9th May 2019
On 9 May 2019, the MPP published a prioritisation framework that outlines a precise methodology for assessing candidate medicines that could play a major role in the MPP’s expanded mandate into new disease therapies beyond HIV, hepatitis C and tuberculosis.
The framework considers a number of criteria, including the clinical importance of specific medicines, guided, where possible, by World Health Organization (WHO) existing assessments and aligned with established global health priorities. Also under consideration will be potential access challenges relating to these medicines and the potential for the MPP to address these challenges through its public health-oriented licensing and patent pooling model. The overall emphasis will be on ensuring greatest public health impact, especially in low- and middle-income countries.
The publication of the framework followed an announcement in May 2018, that the MPP would expand its mandate following a recommendation from the World Health Organization to explore a role for the MPP in relation to other patented essential medicines.